Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck has suspended its research agreement for the development of anti-infective drugs with India-based pharma firm, Ranbaxy.
Subscribe to our email newsletter
Under the agreement, Ranbaxy was expected to receive around $100m payment from the American drug company, Merck, Economic Times reported.
Reportedly, Merck has transferred the research programs to a wholly subsidiary of Dr Reddy’s, Aurigine.
Ranbaxy and MSD, the Indian arm of Merck & Co spokespersons said that they have suspended the drug discovery programme for the development of anti-bacterial and antifungal medicines, while, a spokesperson from Dr Reddy’s declined to comment, quoted Economic Times.